Cefradine: Difference between revisions

	WikiDoc Resources for Cefradine
Articles
Most recent articles on Cefradine Most cited articles on Cefradine Review articles on Cefradine Articles on Cefradine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Cefradine Images of Cefradine Photos of Cefradine Podcasts & MP3s on Cefradine Videos on Cefradine
Evidence Based Medicine
Cochrane Collaboration on Cefradine Bandolier on Cefradine TRIP on Cefradine
Clinical Trials
Ongoing Trials on Cefradine at Clinical Trials.gov Trial results on Cefradine Clinical Trials on Cefradine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Cefradine NICE Guidance on Cefradine NHS PRODIGY Guidance FDA on Cefradine CDC on Cefradine
Books
Books on Cefradine
News
Cefradine in the news Be alerted to news on Cefradine News trends on Cefradine
Commentary
Blogs on Cefradine
Definitions
Definitions of Cefradine
Patient Resources / Community
Patient resources on Cefradine Discussion groups on Cefradine Patient Handouts on Cefradine Directions to Hospitals Treating Cefradine Risk calculators and risk factors for Cefradine
Healthcare Provider Resources
Symptoms of Cefradine Causes & Risk Factors for Cefradine Diagnostic studies for Cefradine Treatment of Cefradine
Continuing Medical Education (CME)
CME Programs on Cefradine
International
Cefradine en Espanol Cefradine en Francais
Business
Cefradine in the Marketplace Patents on Cefradine
Experimental / Informatics
List of terms related to Cefradine

Cefradine
Clinical data
Trade names	Intracef, Velocef
AHFS/Drugs.com	International Drug Names
MedlinePlus	a601206
Routes of; administration	Oral, IM, IV
ATC code	J01DB09 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	Well absorbed
Protein binding	<10%
Metabolism	Nil
Elimination half-life	0.9 hours
Excretion	Renal, unchanged
Identifiers
	IUPAC name (6R,7R)-7-{[(2R)-2-amino-2-(1-cyclohexa-1,4-; dienyl)acetyl]amino}-3-methyl-8-oxo-5-thia-; 1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;
CAS Number	38821-53-3 ;
PubChem CID	38103;
DrugBank	DB01333 ;
ChemSpider	34933 ;
UNII	9YA6SX5S4D;
KEGG	D00264 ;
ChEBI	CHEBI:3547 ;
ChEMBL	ChEMBL1604 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C16H19N3O4S
Molar mass	349.406 g/mol
3D model (JSmol)	Interactive image;
	SMILES O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)[C@@H](C/3=C/C\C=C/C\3)N)C)C(=O)O;
	InChI InChI=1S/C16H19N3O4S/c1-8-7-24-15-11(14(21)19(15)12(8)16(22)23)18-13(20)10(17)9-5-3-2-4-6-9/h2-3,6,10-11,15H,4-5,7,17H2,1H3,(H,18,20)(H,22,23)/t10-,11-,15-/m1/s1 ; Key:RDLPVSKMFDYCOR-UEKVPHQBSA-N ;
(verify)

VisualWikitext

Latest revision as of 18:32, 9 April 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Cefradine (INN) (formerly cephradine BAN) is a first generation cephalosporin antibiotic.

Indications

It has similar spectrum of activity to cefalexin. RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia). (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Velosef is generally effective in the eradication of streptococci from the nasopharynx; substantial data establishing the efficacy of Velosef in the subsequent prevention of rheumatic fever are not available at present.) OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci. SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci. URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis). The high concentrations of cephradine achievable in the urinary tract will be effective against many strains of enterococci for which disc susceptibility studies indicate relative resistance. It is to be noted that among beta-lactam antibiotics, ampicillin is the drug of choice for enterococcal urinary tract (E. faecalis) infection.

Formulations

Capsules containing 250 mg or 500 mg, Syrup containing 250 mg/5 ml, or vials for injection containing 500 mg or 1 g.

Brand Names

International Brands Velocef, Infexin (by Merck Pvt, Ltd) Intracef (by Beximco Pharma) SEFRIL(The ACME laboratories Ltd., Bangladesh), REOCEF(Rephco Pharmaceuticals Ltd., Bangladesh). Lebac (by Square pharmaceuticals Ltd., Bangladesh)

References

British National Formulary 45 March 2003

Template:Antibiotic-stub

@@ Line 1: / Line 1: @@
-{{drugbox |
+{{Drugbox
+| verifiedrevid = 443510316
 | IUPAC_name = (6''R'',7''R'')-7-{[(2''R'')-2-amino-2-(1-cyclohexa-1,4-<br>dienyl)acetyl]amino}-3-methyl-8-oxo-5-thia-<br>1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
-| image =
+| image = Cefradine Wiki Str.png
+<!--Clinical data-->
+| tradename =  Intracef, Velocef
+| Drugs.com = {{drugs.com|international|cefradine}}
+| MedlinePlus = a601206
+| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
+| pregnancy_US = <!-- A / B            / C / D / X -->
+| pregnancy_category =
+| legal_status = Rx-only
+| routes_of_administration = Oral, [[Intramuscular injection|IM]], [[Intravenous therapy|IV]]
+<!--Pharmacokinetic data-->
+| bioavailability = Well absorbed
+| protein_bound = <10%
+| metabolism = Nil
+| elimination_half-life = 0.9 hours
+| excretion = [[Kidney|Renal]], unchanged
+<!--Identifiers-->
+| CASNo_Ref = {{cascite|correct|CAS}}
+| CAS_number_Ref = {{cascite|correct|??}}
 | CAS_number = 38821-53-3
 | ATC_prefix = J01
 | ATC_suffix = DB09
 | PubChem = 38103
-| DrugBank =
+| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
-| C = 16 | H = 19 | N = 3 | O = 4 | S = 1
+| DrugBank = DB01333
+| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
+| ChemSpiderID = 34933
+| UNII_Ref = {{fdacite|correct|FDA}}
+| UNII = 9YA6SX5S4D
+| KEGG_Ref = {{keggcite|correct|kegg}}
+| KEGG = D00264
+| ChEBI_Ref = {{ebicite|correct|EBI}}
+| ChEBI = 3547
+| ChEMBL_Ref = {{ebicite|correct|EBI}}
+| ChEMBL = 1604
+<!--Chemical data-->
+| C=16 | H=19 | N=3 | O=4 | S=1
 | molecular_weight = 349.406 g/mol
-| bioavailability = Well absorbed
+| smiles = O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)[C@@H](C/3=C/C\C=C/C\3)N)C)C(=O)O
-| protein_bound = <10%
+| InChI = 1/C16H19N3O4S/c1-8-7-24-15-11(14(21)19(15)12(8)16(22)23)18-13(20)10(17)9-5-3-2-4-6-9/h2-3,6,10-11,15H,4-5,7,17H2,1H3,(H,18,20)(H,22,23)/t10-,11-,15-/m1/s1
-| metabolism = Nil
+| InChIKey = RDLPVSKMFDYCOR-UEKVPHQBBU
-| elimination_half-life = 0.9 hours
+| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
-| excretion = [[Kidney|Renal]], unchanged
+| StdInChI = 1S/C16H19N3O4S/c1-8-7-24-15-11(14(21)19(15)12(8)16(22)23)18-13(20)10(17)9-5-3-2-4-6-9/h2-3,6,10-11,15H,4-5,7,17H2,1H3,(H,18,20)(H,22,23)/t10-,11-,15-/m1/s1
-| pregnancy_AU =  <!-- A / B1 / B2 / B3 / C / D / X -->
+| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
-| pregnancy_US =  <!-- A / B            / C / D / X -->
+| StdInChIKey = RDLPVSKMFDYCOR-UEKVPHQBSA-N
-| pregnancy_category =
-| legal_status = Rx-only
-| routes_of_administration = Oral, [[Intramuscular injection|IM]], [[Intravenous therapy|IV]]
 }}
+__NOTOC__
 {{SI}}
-{{EH}}
+{{CMG}}
+== Overview ==
-==Overview==
+'''Cefradine''' ([[International Nonproprietary Name|INN]]) (formerly '''cephradine''' [[British Approved Name|BAN]]) is a first generation  [[cephalosporin]] [[antibiotic]].
-'''Cefradine''' ([[International Nonproprietary Name|INN]]) or '''cephradine''' (former [[British Approved Name|BAN]]) is a first generation  [[cephalosporin]] [[antibiotic]].
 ==Indications==
 It has similar spectrum of activity to [[cefalexin]].
+RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia).
+(Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Velosef is generally effective in the eradication of streptococci from the nasopharynx; substantial data establishing the efficacy of Velosef in the subsequent prevention of rheumatic fever are not available at present.)
+OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci.
+SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci.
+URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis). The high concentrations of cephradine achievable in the urinary tract will be effective against many strains of enterococci for which disc susceptibility studies indicate relative resistance. It is to be noted that among beta-lactam antibiotics, ampicillin is the drug of choice for enterococcal urinary tract (E. faecalis) infection.
-==Dosage==
+==Formulations==
-Dosage by mouth for adults is 250–500 mg every 6 hours, or 500 mg to 1 g every 12 hours. In severe infections up to 1 g every 6 hours may be used. Dosages for children are based upon their weight with 25–50 mg/kg total daily dose given in 2–4 divided doses.
+Capsules containing 250 mg or 500 mg, Syrup containing 250 mg/5 ml, or vials for injection containing 500 mg or 1 g.
-==Formulations==
+==Brand Names==
-Caspules containing 250 mg or 500 mg, Syrup containing 250 mg/5 ml, or vials for injection containing 500 mg or 1 g.
+International Brands Velocef, Infexin (by Merck Pvt, Ltd) Intracef (by Beximco Pharma) SEFRIL(The ACME laboratories Ltd., Bangladesh), REOCEF(Rephco Pharmaceuticals Ltd., Bangladesh). Lebac (by Square pharmaceuticals Ltd., Bangladesh)
 ==References==
@@ Line 40: / Line 78: @@
 {{CephalosporinAntiBiotics}}
+[[Category:Drug]]
 [[Category:Cephalosporin antibiotics]]
-{{SIB}}
+[[Category:Enantiopure drugs]]
+{{antibiotic-stub}}
-[[pt:Cefradina]]
-[[th:เซฟราดีน]]
-{{WikiDoc Help Menu}}
-{{WS}}

v t e Antibacterials: cell wall disruption (J01C-J01D)
Internal to membrane/ (inhibit peptidoglycan subunit synthesis and transport)	Template:Navbox subgroup
Glycopeptide/ (inhibit PG chain elongation)	Vancomycin # (Oritavancin, Telavancin) · Teicoplanin (Dalbavancin) · Ramoplanin
Beta-lactams/ (inhibit cross-links with PBP)	Template:Navbox subgroup
Other	Template:Navbox subgroup
# = WHO-EM